# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-260678
Filing Date
2026-06-08
Accepted
2026-06-08 07:15:53
Documents
80
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | sptx-20260331.htm iXBRL | 10-Q | 2797581
2 | EX-31.1 | sptx-ex31_1.htm | EX-31.1 | 22309
3 | EX-31.2 | sptx-ex31_2.htm | EX-31.2 | 21975
4 | EX-32.1 | sptx-ex32_1.htm | EX-32.1 | 11295
5 | EX-32.2 | sptx-ex32_2.htm | EX-32.2 | 11305
| Complete submission text file | 0001193125-26-260678.txt |  | 9734007

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | sptx-20260331.xsd | EX-101.SCH | 1192632
84 | EXTRACTED XBRL INSTANCE DOCUMENT | sptx-20260331_htm.xml | XML | 1551627

Mailing Address 6 TIDE STREET SUITE 400 BOSTON MA 02110
Business Address 6 TIDE STREET SUITE 400 BOSTON MA 02110 617-807-4062
Seaport Therapeutics, Inc. (Filer) CIK: 0002042347 (see all company filings)

EIN.: 992235719 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43254 | Film No.: 261071017
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)